CCL2 and fatty liver disease: This study is the first to describe the mechanism of CCR2 inhibitor in hepatic steatosis, and supports the involvement cross talk between MCP-1 and CCR2, which could activate inflammatory responses and blunt insulin signaling in the fatty liver.